How have PTCHF shares performed in 2024?

PureTech Health's stock was trading at $2.38 at the beginning of the year. Since then, PTCHF stock has increased by 16.8% and is now trading at $2.78. View the best growth stocks for 2024 here .

Are investors shorting PureTech Health?

PureTech Health saw a increase in short interest in March. As of March 31st, there was short interest totaling 68,400 shares, an increase of 38.7% from the March 15th total of 49,300 shares. Based on an average trading volume of 56,200 shares, the days-to-cover ratio is currently 1.2 days. View PureTech Health's Short Interest .

How do I buy shares of PureTech Health?

Shares of PTCHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:PTCHF

PureTech Health (PTCHF) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free PTCHF Stock Alerts

$2.78

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $2.78
▼
$2.78
50-Day Range: $2.30
▼
$2.85
52-Week Range: $1.69
▼
$3.10

Volume: N/A
Average Volume: 36,952 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings Short Interest

Get PureTech Health alerts:

Ad Eagle Publishing

Options trading has suddenly become more reliable.

When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.

Click here to see how simple option trades win 96% of the time.

About PureTech Health Stock (OTCMKTS:PTCHF)

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PTCHF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTCHF Stock News Headlines

April 15, 2024 | americanbankingnews.com

PureTech Health plc (OTCMKTS:PTCHF) Short Interest Update

April 9, 2024 | bizjournals.com

PureTech’s founding CEO takes new role as head of Boston biotech

April 17, 2024 | TradeSmith (Ad)

1970’s computer coder issues shocking A.I. warning

Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.

March 23, 2024 | seekingalpha.com

PureTech Health: Repeat What Works

March 13, 2024 | lse.co.uk

PureTech Health celebrates drug designation for LYT-200 from US FDA

March 13, 2024 | markets.businessinsider.com

PureTech Health Gets FDA's Orphan Drug Designation For LYT-200 In Acute Myeloid Leukemia

February 24, 2024 | finance.yahoo.com

PureTech Health plc (PTCHF)

December 20, 2023 | finance.yahoo.com

PureTech Year End Update and Outlook for 2024

April 17, 2024 | TradeSmith (Ad)

1970’s computer coder issues shocking A.I. warning

December 16, 2023 | morningstar.com

PureTech Health PLC PRTC

August 29, 2023 | lse.co.uk

PureTech narrows interim loss despite "stormy market challenges"

August 1, 2023 | marketwatch.com

PureTech Health Gets $11.4Mln to Advance Development of LYT-300

June 13, 2023 | finance.yahoo.com

Results of PureTech's Annual General Meeting

June 7, 2023 | lse.co.uk

PureTech Health's Akili launches ADHD immersive treatment in US

May 9, 2023 | finance.yahoo.com

PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

May 4, 2023 | finance.yahoo.com

PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

April 29, 2023 | finance.yahoo.com

Full Year 2023 PureTech Health PLC Earnings Call

April 28, 2023 | lse.co.uk

PureTech Health yearly loss widens but remains optimistic

March 25, 2023 | proactiveinvestors.com

Nike, UBS, MGC Pharmaceuticals, NVIDIA, Travelzoo top the analyst calls of the week

March 21, 2023 | lse.co.uk

PureTech Health says Karuna KArXT trial receives positive results

February 14, 2023 | finance.yahoo.com

PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

January 21, 2023 | reuters.com

PRTC.L - | Stock Price & Latest News | Reuters

January 13, 2023 | uk.finance.yahoo.com

PureTech Health plc (PRTC.L)

November 30, 2022 | msn.com

PureTech Announces New Therapeutic Candidate LYT-310, An Oral CBD Prodrug

November 30, 2022 | finance.yahoo.com

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

November 1, 2022 | finance.yahoo.com

PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

October 13, 2022 | finance.yahoo.com

The Petri Dish: 1910 Genetics hires CBO; PureTech calls off merger

See More Headlines

Receive PTCHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:PTCHF
CUSIP: N/A
CIK: 1782999
Web: www.puretechhealth.com
Phone: (617) 482-2333
Fax: N/A
Employees: 111
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Ms. Daphne Zohar (Age 53)
Founder, CEO & Executive Director
Comp: $1.01M
Dr. Bharatt M. Chowrira J.D. (Age 59)
Ph.D., President & Executive Director
Comp: $800.55k
Dr. Robert S. Langer Jr. (Age 75)
Ph.D., Co-Founder & Non-Executive Director
Comp: $145k
Dr. David R. Elmaleh Ph.D. (Age 76)
Co-Founder & Senior Advisor
Ms. Allison Mead Talbot
Head of Communications & Investor Relations
Mr. Spencer Ball
Senior Vice President of Human Resources
Dr. Eric Elenko Ph.D. (Age 51)
Chief Innovation & Strategy Officer
Ms. Aleksandra Filipovic M.D.
Ph.D., Head of Oncology
Ms. Cheryl Murphy Ph.D.
Head of Grants Management & Strategy
Ms. Anita Terpstra J.D.
Ph.D., Senior VP & Head of Intellectual Property

Key Competitors

View All Competitors

PTCHF Stock Analysis - Frequently Asked Questions

How have PTCHF shares performed in 2024?: PureTech Health's stock was trading at $2.38 at the beginning of the year. Since then, PTCHF stock has increased by 16.8% and is now trading at $2.78.
View the best growth stocks for 2024 here.
Are investors shorting PureTech Health?: PureTech Health saw a increase in short interest in March. As of March 31st, there was short interest totaling 68,400 shares, an increase of 38.7% from the March 15th total of 49,300 shares. Based on an average trading volume of 56,200 shares, the days-to-cover ratio is currently 1.2 days.
View PureTech Health's Short Interest.
How do I buy shares of PureTech Health?: Shares of PTCHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PTCHF) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial